GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » 23andMe Holding Co (NAS:ME) » Definitions » EBIT

ME (23andMe Holding Co) EBIT : $-270.7 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is 23andMe Holding Co EBIT?

23andMe Holding Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-58.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-270.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. 23andMe Holding Co's annualized ROC % for the quarter that ended in Sep. 2024 was -103.66%. 23andMe Holding Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -328.38%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. 23andMe Holding Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -844.39%.


23andMe Holding Co EBIT Historical Data

The historical data trend for 23andMe Holding Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

23andMe Holding Co EBIT Chart

23andMe Holding Co Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
EBIT
-213.76 -185.20 -254.15 -324.01 -321.36

23andMe Holding Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -76.48 -80.91 -58.92 -71.96 -58.93

Competitive Comparison of 23andMe Holding Co's EBIT

For the Diagnostics & Research subindustry, 23andMe Holding Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


23andMe Holding Co's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, 23andMe Holding Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where 23andMe Holding Co's EV-to-EBIT falls into.



23andMe Holding Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-270.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


23andMe Holding Co  (NAS:ME) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

23andMe Holding Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-235.704 * ( 1 - 0.07% )/( (227.681 + 226.743)/ 2 )
=-235.5390072/227.212
=-103.66 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=368.047 - 60.269 - ( 169.971 - max(0, 152.857 - 232.954+169.971))
=227.681

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=318.936 - 56.24 - ( 126.601 - max(0, 152.831 - 188.784+126.601))
=226.743

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

23andMe Holding Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-235.704/( ( (73.636 + max(-107.563, 0)) + (69.918 + max(-105.766, 0)) )/ 2 )
=-235.704/( ( 73.636 + 69.918 )/ 2 )
=-235.704/71.777
=-328.38 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.099 + 14.747 + 20.471) - (60.269 + 68.015 + 15.596)
=-107.563

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.446 + 14.846 + 22.507) - (56.24 + 69.751 + 17.574)
=-105.766

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

23andMe Holding Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-270.713/32.060
=-844.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


23andMe Holding Co EBIT Related Terms

Thank you for viewing the detailed overview of 23andMe Holding Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


23andMe Holding Co Business Description

Traded in Other Exchanges
N/A
Address
349 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
Executives
Kathy L Hibbs officer: See Remarks C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
William G Richards officer: Head of Therapeutics Discovery 160 KELLY AVE, HALF MOON BAY CA 94019
Richard H Scheller director C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Joseph Anthony Selsavage officer: Interim CFO 490 HILL STREET, APT 5, SAN FRANCISCO CA 94114
Kenneth J. Hillan officer: Head of Therapeutics C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Evan Lovell director, officer: Chief Financial Officer 27 SOUTH PARK STREET, SUITE 200, SAN FRANCISCO CA 94107
Hernandez Sandra R Md director BLACKBAUD INC, 2000 DANIEL ISLAND DRIVE, CHARLESTON SC 29492
Paul D Johnson officer: VP, General Manager-Consumer 440 N BARRANCA AVE #3550, COVINA CA 91723
Tracy Keim officer: See Remarks 6107 ARROWROOT LANE, RANCHO PALOS VERDES CA 90275
Steven Lemon officer: Vice President, Engineering 1020 CHERRY AVENUE, SAN JOSE CA 95125
Steven J Schoch officer: See Remarks 2748 BUSH STREET, SAN FRANCISCO CA 94115
Frederick Mark Kohler officer: Vice President, People 1004 UNION STREET, ALAMEDA CA 94501
Sequoia Capital Global Growth Ii Principals Fund, L.p. 10 percent owner 2800 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Abeec 2.0, Llc 10 percent owner 171 MAIN STREET, SUITE 259, LOS ALTOS CA 94022
Anne Wojcicki director, 10 percent owner, officer: Chief Executive Officer C/O AJAX I HOLDINGS, LLC, 667 MADISON AVENUE, NEW YORK NY 10606